Bionano Genomics, Inc BNGO 深 滬
已收盤 10-24 16:00:00 美东时间
1.93
+0.020
+1.05%
華盛通- 最 高1.96
- 今 開1.93
- 成交量 24.83万股
- 最 低 1.9152
- 昨 收 1.91
- 總市值 1882.77万
- 52周最高 22.80
- 市盈率 靜 --
- 換手率 2.55%
- 52周最低 1.50
- 委 比 -72.20%
- 總股本 975.53万
- 歷史最高 9414.00
- 量 比 0.66
- 振 幅 2.35%
- 歷史最低 1.9152
- 每 手 1
- 風險率 5.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Bionano to Participate in the H.C. Wainwright @ Home Event
Bionano Genomics, Inc. announces that its CEO, Erik Holmlin, PhD, will participate in the H.C. Wainwright @ Home Event on October 15, 2025. The event will take place from 10:00 a.m. to 11:00 a.m. ET. A live webcast and post-event recording will be available via the provided link. Bionano, a provider of genome analysis solutions, offers optical genome mapping (OGM) technology, diagnostic services, and software for various research applications.
10-07 12:00
Why BioNano Genomics (BNGO) Stock Is Getting Hammered Tuesday
BioNano Genomics shares are trading sharply lower in Tuesday's session. The company announced the pricing of a $10 million public offering.
09-17 00:53
Bionano Genomics slides after pricing $10M equity offering
Bionano Genomics (NASDAQ:BNGO) has priced a public offering of 5M shares of its common stock (or equivalents) with accompanying Series E and short-term Series F warrants, at a combined public offering...
09-16 21:28
Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering
Bionano Genomics announced a public offering of 5 million shares of common stock and accompanying Series Warrants, priced at $2.00 per share. The Series E warrants expire in five years, while the short-term Series F warrants expire in 18 months. The company expects gross proceeds of approximately $10 million, with potential additional proceeds of $20 million if the warrants are fully exercised. H.C. Wainwright & Co. is the placement agent. Procee...
09-16 13:10
Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology
Bionano Genomics announced the publication of a book seriesvolume dedicated to chromoanagenesis, a catastrophic genome rearrangement linked to cancer. Optical genome mapping (OGM) is highlighted as a powerful tool for detecting and analyzing complex chromoanagenesis events, offering a genome-wide, high-resolution view of structural variants that traditional methods struggle to address. The volume includes studies on acute myelogenous leukemia (AM...
09-16 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Check-Cap (NASDAQ:CHEK) shares rose 225.1% to $2.42 during Monday's re...
09-16 01:06
CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders
Bionano Laboratories announced that CMS approved a new Category I CPT code (81354) for optical genome mapping (OGM) in detecting structural variations related to constitutional genetic disorders. Priced at $1263.53, the code is higher than existing microarray codes (81228: $900 and 81229: $1160). This follows the approval of code 81195 for hematologic malignancies. Bionano offers OGM-Dx Postnatal and Prenatal Whole Genome SV tests, expected to be...
09-15 11:00
Bionano Genomics Selected For Sole Source Contract By NIH For Optical Genome Mapping Reagents And Instruments; No Contract Value Disclosed
https://sam.gov/opp/7a19a6e8954c4de1a128b841e2018400/view DescriptionThis is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.This
09-02 23:43
Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. The presentation will be available via webcast and replay through Bionano's website for 30 days.
08-25 12:00
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Raises Price Target to $11
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and raises the price target from $10 to $11.
08-18 19:27
